GRPR-Targeted Radioligand Therapy in Prostate Cancer: The A9-0631 and A9-0642 Trial

/in , , , , /by

A new first-in-human study is testing whether GRPR-targeted radiopharmaceuticals can extend precision oncology beyond the PSMA and SSTR frameworks. The trial combines two therapeutic agents, 177Lu-A9-0631 and 225Ac-A9-0642, with GRPR imaging using 68Ga-A9-6217 or low-dose 177Lu-A9-0631 in patients with GRPR-positive solid tumors. GRPR, or gastrin-releasing peptide receptor, is an appealing target because it is overexpressed […]

Read more

ARTO Trial Final Results: Long-Term Survival Benefit of SBRT Added to Abiraterone in Oligometastatic mCRPC

/in , , /by

The phase 2 ARTO trial findings, published on The Lancet, provides stronger evidence that metastasis-directed SBRT can improve outcomes in oligometastatic castration-resistant prostate cancer. In this randomized study, 157 patients were enrolled across 16 academic and community centers in Italy and assigned 1:1 to abiraterone plus ADT with or without SBRT to all visible metastatic […]

Read more

Bavdegalutamide Plus Abiraterone in Metastatic Prostate Cancer: Phase Ib Safety and Activity Results

/in , , /by

Bavdegalutamide (ARV-110) is an oral androgen receptor degrader designed to address resistance to androgen-receptor–targeted therapy in metastatic prostate cancer. In this phase 1b study, it was combined with abiraterone in patients whose disease was progressing on abiraterone, with the goal of testing safety, pharmacokinetics, and early signs of antitumor activity. The trial enrolled 45 patients, […]

Read more

Another Phase 1/2 Trial With SX-682, Combined With Docetaxel This Time

/in , , , /by

SX-682 is moving into a new clinical context. After an ongoing trial in prostate cancer with androgen receptor pathway inhibitors such as apalutamide and enzalutamide, the CXCR1/2 inhibitor is now being studied with docetaxel in recurrent/metastatic head and neck squamous cell carcinoma, salivary gland carcinoma, and advanced prostate cancer. That matters because docetaxel is not […]

Read more

Phase 1 Trial for a New PSMA Radioligand 177Lu‑PSMA‑VG01

/in , , /by

177Lu‑PSMA‑VG01 is a next‑generation, small‑molecule PSMA‑targeting radiopharmaceutical designed to refine what 177Lu‑PSMA‑617 (Pluvicto) has already achieved. It uses a high‑affinity ligand to deliver the beta‑emitter lutetium‑177 directly to PSMA‑expressing tumor cells, aiming for greater tumor dosing with less exposure of healthy tissue. A new phase 1 trial is testing its dosimetry and side effects on […]

Read more

Dual-Targeting PSMA And FRα Drug Conjugate Advances to U.S. Trial for Prostate Cancer

/in , , , /by

MVB-101 (aka CBP-1018) is a new clinical-stage drug conjugate for prostate cancer simultaneously targets PSMA and folate receptor alpha (FRα) to overcome tumor heterogeneity. The drug is a bivalent peptide-like drug conjugate roughly one-fiftieth the size of a traditional antibody drug conjugate, designed to diffuse more rapidly into solid tumors. It delivers monomethyl auristatin E […]

Read more

Phase 1 RIALTO Trial: Radiotherapy for Metastatic Prostate Cancer With Incomplete Hormone Response

/in , , /by

The RIALTO trial challenges decades of oncology dogma that treating the prostate becomes irrelevant once cancer spreads. For patients with de novo metastasized prostate cancer who show incomplete PSA-response (PSA >0.2 ng/ml after six months of combined ADT+ARPI), the prostate may function as a persistent tumor reservoir continuously seeding metastases. Local radiotherapy to the prostate […]

Read more

Phase 2 Trial for 61Cu-NU101 vs 18F-Piflufolastat in Metastatic Prostate Cancer

/in , , /by

61Cu-NU101 is a new PSMA-targeted PET/SPECT tracer for prostate cancer that showed promise in phase 1, detecting more lesions than 18F-piflufolastat (Pylarify) in half of the 8 patients studied, with lower background uptake and no side effects. The key advantage is its 3.3-hour half-life, compared to 68 minutes for 68Ga-PSMA-11 and 109 minutes for 18F-piflufolastat. […]

Read more

UPDATE: Memantine for Neuroendocrine Prostate Cancer, Early Efficacy Signals

/in , , /by

Prostate cancer can become harder to treat when it changes from the usual adenocarcinoma form into neuroendocrine prostate cancer, or NEPC. A recent study suggests that this transition may begin earlier than expected, during an intermediate phase when the cells are still partly prostate-like but are already starting to acquire neuroendocrine features. A central finding […]

Read more

Confirmed Efficacy of Rucaparib in BRCA-Mutated mCRPC

/in , , /by

Rucaparib continues to strengthen its position in BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that progresses despite hormonal therapy, with TRITON3 trial confirming not only its efficacy but also a predictable and manageable safety profile. In this phase 3 study of chemotherapy-naïve patients progressing after one prior androgen receptor pathway […]

Read more